Your English writing platform
Discover LudwigExact(4)
The first clinical trial agent that targets Bcl-2 is oblimersen sodium (a Bcl-2 antisense oligonucleotide compound).
No anti-tumor therapy for stage IV breast cancer was permitted within 28 days before administration of the trial agent.
The ORR in treatment- naïve patients varies between 5.2% and 47% depending upon the trial, agent utilized, and type of analysis (independent vs investigator).
Although in randomised controlled trials the proportion of CAM users should be equal in each trial arm, the trial outcome could theoretically be influenced if a CAM specifically interacts with the trial agent but not with the control medication/placebo.
Similar(56)
Exclusion criteria were (i) the use of (oral) experimental trial agents, (ii) age <18 years, and (iii) the use of oral anticancer drugs for non-malignant diseases.
On half of the trials Agent B or the computer could infer the color of his own hat ('Yes' response) whereas, on the other trials, Agent B or the computer could not infer the color of his own hat ('No' response).
In clinical trials, agents including small molecule inhibitors and antibody-based pharmaceuticals can be given concurrently or continually with conventional therapy (Hallek et al., 2014).
The first is that, in head-to-head trials, agents that differ in action can lead to similar clinical responses.
In randomized clinical trials, agents targeting the proinflammatory cytokine tumor necrosis factor (TNF -α, such as TNF -αnoclonal antibody infliximab, have produced suchificasthemonoclonal of signs antibodytoms infliximabents [ 4].
However, clinical trials to test agents that could halt these cellular mechanisms have met largely with failure.
But at Mr. Medina's trial, the agent testified that Mr. Medina had not spoken to him about the crime.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com